Eriglip M 500mg/20mg Tablets: A Combination Approach to Managing Diabetes

Eriglip M 500mg/20mg tablets combine the potent hypoglycemic actions of metformin (500mg) with the selective DPP-4 inhibitor teneligliptin (20mg). This dual action provides comprehensive blood sugar control, effectively reducing both fasting and postprandial hyperglycemia.

Metformin: A first-line choice for managing type 2 diabetes, metformin demonstrates efficacy through multiple mechanisms, including enhancing insulin sensitivity and decreasing glucose production in the liver.

Teneligliptin: This DPP-4 inhibitor specifically targets incretin hormone activity, promoting insulin secretion and reducing glucagon release, further enhancing blood sugar control.

Eriglip M tablets offer:
* Effective Blood Sugar Control: Promotes glycemic control by lowering both fasting and postprandial glucose levels.
* Comprehensive Management: Provides a dual-action approach for improved treatment effectiveness.
* Convenient Dosage: Available in tablet form with a fixed dose of metformin (500mg) and teneligliptin (20mg).

Eriglip M is suitable for adults diagnosed with type 2 diabetes, often recommended as part of an overall diabetes management plan alongside lifestyle modifications.

Disclaimer: Consult your healthcare provider before starting any new medication regimen. This description is for informational purposes only and does not substitute professional medical advice.